Pharmacological properties of the naturally occurring Ala(457)Pro variant of the human norepinephrine transporter.
Recently, another research group has reported an almost complete loss of function of the human norepinephrine transporter (hNET) in patients who had orthostatic intolerance and who were heterozygous for a guanine to cytosine exchange, resulting in a hNET Ala(457)Pro variant. To explore the reason for the deficiency in NET function, we compared in detail the pharmacology of the Ala(457)Pro variant with that of the wild-type hNET in COS-7 cells transiently transfected with hNET or Ala(457)Pro cDNA. Compared to the wild-type hNET, the Ala(457)Pro variant exhibited a five-fold higher affinity for cocaine, but a two-fold lower affinity for the NET inhibitor nisoxetine, and an unchanged affinity for the antidepressant desipramine. Plasma membrane expression (measured as Bmax of [3H]nisoxetine binding) of the Ala(457)Pro variant was only 40% of that of the wild-type hNET. The Ala(457)Pro variant showed a six- to 10-fold decrease in affinity for the substrates dopamine and 1-methyl-4-phenylpyridinium (MPP(+)). Compared with the wild-type hNET, the maximum rate (V(max)) of norepinephrine uptake by the Ala(457)Pro variant was slightly reduced, whereas the turnover number (calculated from V(max)/B(max)) was approximately two-fold higher. However, the Ala(457)Pro variant exhibited a 50-fold higher K(m) (i.e. lower apparent affinity) for norepinephrine than the wild-type hNET. Thus, the previously reported loss of function of the Ala(457)Pro variant associated with orthostatic intolerance is only partly due to a reduction in plasma membrane expression of the transporter, and is mainly caused by the pronounced reduction in the apparent affinity of norepinephrine.
Paczkowski
Filip A
FA
Department of Physiology and Pharmacology, School of Biomedical Sciences, The University of Queensland, Brisbane, Queensland, Australia.
Bönisch
Heinz
H
Bryan-Lluka
Lesley J
LJ
D018759:Adrenergic Uptake Inhibitors / Q000494:pharmacology; D019943:Amino Acid Substitution / Q000235:genetics; D000818:Animals; D001665:Binding Sites; D019556:COS Cells; D003042:Cocaine / Q000494:pharmacology / Q000652:urine; D003891:Desipramine / Q000494:pharmacology; D018765:Dopamine Uptake Inhibitors / Q000494:pharmacology; D005473:Fluoxetine / Q000031:analogs & derivatives* / Q000494:pharmacology; D049452:Green Fluorescent Proteins; D006801:Humans; D008164:Luminescent Proteins / Q000378:metabolism; D016297:Mutagenesis, Site-Directed; D009638:Norepinephrine / Q000037:antagonists & inhibitors / Q000378:metabolism; D050484:Norepinephrine Plasma Membrane Transport Proteins; D020033:Protein Isoforms / Q000235:genetics / Q000378:metabolism / Q000494:pharmacology; D027981:Symporters / Q000235:genetics* / Q000378:metabolism / Q000494:pharmacology*; D014162:Transfection
D018759:Adrenergic Uptake Inhibitors; D018765:Dopamine Uptake Inhibitors; D008164:Luminescent Proteins; D050484:Norepinephrine Plasma Membrane Transport Proteins; D020033:Protein Isoforms; C493227:SLC6A2 protein, human; D027981:Symporters; D005473:Fluoxetine; D049452:Green Fluorescent Proteins; C011386:nisoxetine; D003042:Cocaine; D003891:Desipramine; D009638:Norepinephrine